Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cadrenal Therapeutics, Inc.

NASDAQ: CVKD · Life Sciences · 2 alerts · CIK 1937993

Share price
$1.40Close, Nov 16
Market cap
$4.99M
Shares outstanding
3.57MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cadrenal Therapeutics, Inc. filings on SEC EDGAR ↗

9:24 AM ET 8-K
Other 8-K Filing

Cadrenal Therapeutics Other 8-K Filing

Cadrenal Therapeutics has initiated a formal strategic process to evaluate opportunities to maximize shareholder value, including potential licensing, asset sales, partnerships, or business combinations. The company has engaged Tungsten Advisors as its exclusive financial advisor following alignment with the FDA on a Phase 3 pathway for its lead asset, CAD-1005.

Counterparty
Tungsten Advisors
4:05 PM ET 8-K
Shareholder Meeting

Cadrenal Therapeutics Shareholder Meeting

Cadrenal Therapeutics held its 2026 Annual Meeting of Stockholders where shareholders elected Quang X. Pham as a Class I director and ratified WithumSmith+Brown, P.C. as the independent auditor. Stockholders also approved an amendment to the 2022 Successor Equity Incentive Plan to increase the share pool by 323,542 shares and authorized the issuance of up to 960,000 shares upon the exercise of certain warrants.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.